DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 2 Caligan - 1 David Johnson - 1 Ohtuvayre - 1 Verona's - 1 Verona - 1 MorphoSys - 1 bode - 1
Top related locs:
Verona London MorphoSys Caligan's EBITDA 4Q23 BLCO
Top related orgs:
MorphoSys - 2 Verona Pharma - 1 Caligan Partners - 1 Carlyle Group - 1 FDA - 1 MorphoSys AG - 1 Novartis - 1 pharma - 1

Search resuls for: "pelabresib"


3 mentions found


☆ Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
  + stars: | 2024-11-09 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +7 min
It invests in a concentrated portfolio of small and midcap life sciences companies, using activism as a tool to unlock value. A successful drug like Ohtuvayre would not just increase the life expectancies of patients with COPD, but it would lower costs for both health-care providers and COPD patients. Currently, there are over 8.6 million U.S. COPD patients with over 4 million remaining symptomatic despite treatment from the current commercial therapies. In early pooling analysis, Ohtuvayre showed a 41% reduction in exacerbations in COPD patients, almost double brensocatib. When Caligan announced its Verona position last month, the stock was trading at $33.40 per share or a $2.5 billion enterprise value.
Persons: Caligan, David Johnson, Ohtuvayre, Verona's, Verona, MorphoSys, bode, Ken Squire Organizations: Verona Pharma, Caligan Partners, Carlyle Group, FDA, MorphoSys AG, Novartis, pharma, 13D Locations: Verona, London, MorphoSys, Caligan's
☆ This European biotech company could rally nearly 45%, says Morgan Stanley
  + stars: | 2023-10-13 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +1 min
Recent data for cancer treatment manufacturer MorphoSys AG suggests the German biotech's shares could see a significant rally, according to Morgan Stanley. "Despite increasing competition, our updated analysis suggests peak global sales of $1.6bn for pelabresib," analyst James Quigley wrote in a Friday note. "In addition, while some clinical risk remains, the data so far suggests that MANIFEST-2 has a good chance of success, which should drive significant upside in the shares," Quigley said. Shares have sold off nearly 25% since mid-September, compared to the Nasdaq Biotechnology Index down 4% over the same period. MOR XBI YTD mountain MorphoSys vs SPDR S & P Biotech ETF in 2023.
Persons: Morgan Stanley, James Quigley, Quigley, SPDR, — CNBC's Michael Bloom Organizations: MorphoSys, pelabresib, Nasdaq, MF, P Biotech
☆ Here are Friday's biggest analyst calls: SoFi Technologies, AutoZone, Nvidia, Meta and more
  + stars: | 2023-06-16 | by ( Sarah Min | ) www.cnbc.com   time to read: +6 min
Bank of America downgrades SoFi Technologies to neutral from buy The downgrade follows SoFi' s recent rally. Our C$51 Price Target is 39% above the current stock price and we see close to 3:1 upside/downside skew." UBS upgrades AutoZone to buy from neutral Analyst Michael Lasser raised the price target to $2,900 from $2,800. Wells Fargo initiates Neogen Corporation at overweight and $22 price target Wells Fargo said it liked the company's improving margins. Wells Fargo initiates Bio-Rad Laboratories Inc. at overweight and $550 price target Wells said Bio-Rad's valuation is attractive at current levels.
Persons: Jefferies, John Hecht, LendingClub, Morgan Stanley, Mauricio Serna, Aritzia, Michael Lasser, Carvana, it's, Wells, Ph3, Wells Fargo, Piper Sandler, TD Cowen downgrades, LOE, Michael Bloom Organizations: . Bank of America, Technologies, Nvidia, Bank of America, UBS, West Pharmaceutical Services, Stevanato, MorphoSys, Neogen, Rad Laboratories Inc, SoFi Technologies, Health Companies Locations: EBITDA, 4Q23, BLCO
0 next >>
Total: 3